Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Sinonasal Carcinoma: early-phase trial registry

1 of 3 indexed Sinonasal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Sinonasal Carcinoma: 3 US clinical trials tracked, 1 recruiting.

Sinonasal Carcinoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Thomas Jefferson University, running 1 of these trials.

Enrollment posture brief

Registry condition sinonasal-carcinoma

OPEN 1 | RECR 33% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Sinonasal Carcinoma (this)33%
Open-enrollment share among volume-matched conditions near Sinonasal Carcinoma

Sinonasal Carcinoma lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sinonasal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sinonasal Carcinoma is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Sinonasal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pembrolizumab, Cetuximab Drug
1 trials
Consultation Other
1 trials
Behavioral Intervention Behavioral
1 trials
Medical Device Usage and Evaluation Other
1 trials
Exercise Intervention Other
1 trials
Questionnaire Administration Other
1 trials

US sites by state

Facility locations filed on Sinonasal Carcinoma trials. A trial with sites in several states counts in each.

Pennsylvania 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sinonasal Carcinoma page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sinonasal Carcinoma condition card totals 3 registered trials; most-linked intervention Pembrolizumab, Cetuximab; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.